Article
Integration of gene expression profiling and mutation analysis via RNA sequencing: transitioning the 95-gene classifier to a next-generation platform in early-stage HR+/HER2- breast cancer.
Breast cancer (Tokyo, Japan) - 1 May 2026
Kato Chikage, Sota Yoshiaki, Kitano Sae, Watanabe Akira, Nishida Maiko, Motonari Daitho, Saito Yuria, Kobayashi Masaki, Morita Midori, Sakaguchi Koichi, Shimazu Kenzo, Naoi Yasuto
Abstract excerpt
BACKGROUND: Curebest™ 95GC breast is a multigene assay independently developed in Japan, that utilizes DNA microarray technology to analyze the expression patterns of the 95 genes in breast cancer tissue. It calculates a 95GC score and classifies postoperative recurrence risk into two categories: Low and High. This study aimed to evaluate whether the 95GC score can also be calculated using RNA sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.